ArticleFrontiers in immunology2022
Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 44 citations in OpenAlex.
- Oncolytic viruses in head and neck cancer: therapeutic promise and translational challenges.Frontiers in immunology · 2026Review
- The life cycle of tertiary lymphoid structures in pancreatic cancer-a window of opportunity for immunotherapy.Frontiers in immunology · 2026Review
- Tertiary lymphoid structure can be a potential therapeutic target for head and neck squamous cell carcinoma (Review).Molecular and clinical oncology · 2026Review
- Role of tertiary lymphoid structures in the tumour microenvironment and immunotherapy response of renal cell carcinoma.Clinical and translational medicine · 2025Review
- Combination of low-intensity pulsed ultrasound irradiating immune organs with immune checkpoint blockade augments systemic anti-tumor immunity on low tumor burden 4T-1 breast cancer.Cancer immunology, immunotherapy : CII · 2025Article
- SpaLinker identifies phenotype-associated spatial tumor microenvironment features by integrating bulk and spatial sequencing data.Cell genomics · 2025Article
- Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomes.Cancer gene therapy · 2025Article
- Multiple mechanisms and applications of tertiary lymphoid structures and immune checkpoint blockade.Journal of experimental & clinical cancer research : CR · 2025Review
- The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial.Nature communications · 2025Article
- Dissecting Tertiary Lymphoid Structures in Cancer: Maturation, Localization and Density.Theranostics · 2025Review
- Exploring the role of APRIL in autoimmunity: implications for therapeutic targeting in systemic lupus erythematosus, rheumatoid arthritis, and Sjögren's syndrome.Frontiers in immunology · 2025Review
- Oncolytic herpes simplex virus propagates tertiary lymphoid structure formation via CXCL10/CXCR3 to boost antitumor immunity.Cell proliferation · 2025Article
- Adenoviral Therapy for Cervical Cancer: From Targeted Modification to Immunotherapy.Anti-cancer agents in medicinal chemistry · 2025Review
- Synergy of oncolytic adenovirus and immune checkpoint inhibitors: transforming cancer immunotherapy paradigms.Frontiers in immunology · 2025Review
- Tertiary Lymphoid Structures and Immunotherapy: Challenges and Opportunities.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Tertiary lymphoid structures in renal cell carcinoma: from heterogeneity dissection to translational precision immunotherapy.Frontiers in immunology · 2025Review
- Nanoengineering-armed oncolytic viruses drive antitumor response: progress and challenges.MedComm · 2024Review
- Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Safety, Efficacy, and Biological Data of T-Cell-Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Tertiary lymphoid structures in anticancer immunity.Nature reviews. Cancer · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICI) have provided significant improvement in clinical outcomes for some patients with solid tumors. However, for patients with head and neck cancer, the response rate to ICI monotherapy remains low, leading to the exploration of combinatorial treatment strategies. In this preclinical study, we use an oncolytic adenovirus (Ad5/3) encoding hTNFα and hIL-2 and non-replicate adenoviruses (Ad5) encoding mTNFα and mIL-2 with ICI to achieve superior tumor growth control and improved survival outcomes. The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.